The objective of this project is to develop potential approaches to the therapy of brain and spinal cord injury. One approach is to limit the production or increase the degradation of chondroitin sulfate proteoglycans. We have developed a viral vector that targets a key enzyme in the chondroitin sulfate synthetic pathway and have supplied this vector to our collaborator for testing in animal models of spinal cord injury. We have determined that the viral vector (which is tagged with a fluorescent protein marker) is expressed after injection into the uninjured mouse central nervous system. Current experiments are demonstrating expression after a contusion injury to the mouse spinal cord and also evaluating effects on axonal growth and sprouting and behavioral recovery of function.
|Janecke, Andreas R; Li, Ben; Boehm, Manfred et al. (2016) The phenotype of the musculocontractural type of Ehlers-Danlos syndrome due to CHST14 mutations. Am J Med Genet A 170A:103-15|
|Yi, Jae-Hyuk; Katagiri, Yasuhiro; Yu, Panpan et al. (2014) Receptor protein tyrosine phosphatase ? binds to neurons in the adult mouse brain. Exp Neurol 255:12-8|
|Geller, Herbert M (2013) Above the genome. Int J Dev Neurosci 31:351-2|
|Yi, Jae-Hyuk; Katagiri, Yasuhiro; Susarla, Bala et al. (2012) Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice. J Comp Neurol 520:3295-313|